Burnie Academy
CagriSema: semaglutide plus an amylin copy, in trials

CagriSema: semaglutide plus an amylin copy, in trials

CagriSema is an experimental two-hormone weight-loss shot still in trials and not approved anywhere, including India. Early results look strong but came in below what the maker hoped, so it is years from reach.

13 Jul 2026 · Burnie Academy
cagrisema weight-loss-medicines clinical-trials amylin

You may have heard news about a new weight-loss shot called CagriSema. It sounds exciting because it mixes two hunger-fighting signals in one pen. But here is the honest truth: CagriSema is still being tested in trials. It is NOT approved, NOT sold, and NOT available in India or anywhere else. This short read explains what it is, what the trials really showed, and why you should not try to buy it.

CONTINUE READING FOR FREE

Unlock the complete article

Register with just your mobile number and OTP. No password and no payment.

Use this same phone number in the Burnie mobile app. Your profile, liked articles and favourites will stay synced.

By continuing, you agree to Burnie's Terms and Privacy Policy.

Track your food the honest way

Burnie helps you see your estimated calorie deficit with familiar Indian foods — no fake precision, no guilt trips.

Get Burnie on the App Store

Sign in with the same mobile number you use for Academy. Android public availability is being expanded.